AMARIN CORP PLC\UK Proceeds from Sale and Maturity of Marketable Securities
AMARIN CORP PLC\UK (AMRN) reported Proceeds from Sale and Maturity of Marketable Securities of $88.38 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-07-29
- AMARIN CORP PLC\UK proceeds from sale and maturity of marketable securities for the quarter ending 2026-06-30 was $45.88M, a 8.79% decline year-over-year.
- AMARIN CORP PLC\UK proceeds from sale and maturity of marketable securities for the quarter ending 2026-03-31 was $42.50M, a 22.73% decline year-over-year.
- AMARIN CORP PLC\UK proceeds from sale and maturity of marketable securities for the quarter ending 2025-12-31 was $47.00M, a 0.00% increase year-over-year.
- AMARIN CORP PLC\UK proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $57.00M, a 7.95% increase year-over-year.
- AMARIN CORP PLC\UK proceeds from sale and maturity of marketable securities for fiscal 2025 was $209.30M, a 10.09% decline from fiscal 2024.
- AMARIN CORP PLC\UK proceeds from sale and maturity of marketable securities for fiscal 2024 was $232.80M, a 22.46% increase from fiscal 2023.
- AMARIN CORP PLC\UK proceeds from sale and maturity of marketable securities for fiscal 2023 was $190.11M, a 26.18% decline from fiscal 2022.
- AMARIN CORP PLC\UK proceeds from sale and maturity of marketable securities for fiscal 2022 was $257.52M, a 34.69% decline from fiscal 2021.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $45.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $88.38M 10-Q · filed 2026-07-29 | $135.38M derived: sum of 3 quarters · filed 2026-07-29 | $192.38M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $42.50M 10-Q · filed 2026-04-29 | $89.50M derived: sum of 2 quarters · filed 2026-04-29 | $146.50M derived: sum of 3 quarters · filed 2026-04-29 | $196.80M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $47.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $104.00M derived: sum of 2 quarters · filed 2026-03-02 | $154.30M derived: sum of 3 quarters · filed 2026-07-29 | $209.30M 10-K · filed 2026-03-02 |
| 2025-09-30 | $57.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $107.30M derived: sum of 2 quarters · filed 2026-07-29 | $162.30M 10-Q · filed 2025-10-29 | $209.30M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $50.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $105.30M 10-Q · filed 2026-07-29 | $152.30M derived: sum of 3 quarters · filed 2026-07-29 | $205.10M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $55.00M 10-Q · filed 2026-04-29 | $102.00M derived: sum of 2 quarters · filed 2026-04-29 | $154.80M derived: sum of 3 quarters · filed 2026-04-29 | $225.80M derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | $47.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $99.80M derived: sum of 2 quarters · filed 2026-03-02 | $170.80M derived: sum of 3 quarters · filed 2026-03-02 | $232.80M 10-K · filed 2026-03-02 |
| 2024-09-30 | $52.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $123.80M derived: sum of 2 quarters · filed 2025-10-29 | $185.80M 10-Q · filed 2025-10-29 | $214.91M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $71.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $133.00M 10-Q · filed 2025-07-30 | $162.11M derived: sum of 3 quarters · filed 2026-03-02 | $226.12M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $62.00M 10-Q · filed 2025-05-07 | $91.11M derived: sum of 2 quarters · filed 2026-03-02 | $155.12M derived: sum of 3 quarters · filed 2026-03-02 | $219.19M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $29.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $93.11M derived: sum of 2 quarters · filed 2026-03-02 | $157.19M derived: sum of 3 quarters · filed 2026-03-02 | $190.11M 10-K · filed 2026-03-02 |
| 2023-09-30 | $64.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $128.08M derived: sum of 2 quarters · filed 2024-10-30 | $161.00M 10-Q · filed 2024-10-30 | $177.90M derived: sum of 4 quarters · filed 2025-03-12 |
| 2023-06-30 | $64.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $96.99M 10-Q · filed 2024-07-31 | $113.90M derived: sum of 3 quarters · filed 2025-03-12 | $168.10M derived: sum of 4 quarters · filed 2025-03-12 |
| 2023-03-31 | $32.91M 10-Q · filed 2024-05-01 | $49.82M derived: sum of 2 quarters · filed 2025-03-12 | $104.02M derived: sum of 3 quarters · filed 2025-03-12 | $177.21M derived: sum of 4 quarters · filed 2025-03-12 |
| 2022-12-31 | $16.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $71.11M derived: sum of 2 quarters · filed 2025-03-12 | $144.30M derived: sum of 3 quarters · filed 2025-03-12 | $257.52M 10-K · filed 2025-03-12 |
| 2022-09-30 | $54.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $127.39M derived: sum of 2 quarters · filed 2023-11-01 | $240.61M 10-Q · filed 2023-11-01 | $322.76M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $73.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $186.41M 10-Q · filed 2023-08-02 | $268.56M derived: sum of 3 quarters · filed 2024-02-29 | $327.62M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $113.22M 10-Q · filed 2023-05-03 | $195.36M derived: sum of 2 quarters · filed 2024-02-29 | $254.43M derived: sum of 3 quarters · filed 2024-02-29 | $379.59M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $82.14M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $141.21M derived: sum of 2 quarters · filed 2024-02-29 | $266.37M derived: sum of 3 quarters · filed 2024-02-29 | $394.29M 10-K · filed 2024-02-29 |
| 2021-09-30 | $59.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $184.22M derived: sum of 2 quarters · filed 2022-10-27 | $312.15M 10-Q · filed 2022-10-27 | $427.43M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $125.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $253.08M 10-Q · filed 2022-08-03 | $368.36M derived: sum of 3 quarters · filed 2023-03-01 | $423.63M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $127.92M 10-Q · filed 2022-05-04 | $243.20M derived: sum of 2 quarters · filed 2023-03-01 | $298.47M derived: sum of 3 quarters · filed 2023-03-01 | $412.84M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $115.28M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $170.55M derived: sum of 2 quarters · filed 2023-03-01 | $284.91M derived: sum of 3 quarters · filed 2023-03-01 | $301.99M 10-K · filed 2023-03-01 |
| 2020-09-30 | $55.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $169.64M derived: sum of 2 quarters · filed 2021-11-03 | $186.71M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $114.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $131.44M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $17.08M 10-Q · filed 2021-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |